“Long Term Efficacy, Safety, and Tolerability of Tildrakizumab in Epileptic Patient With Psoriasis and Eczema”. Dermatology Reports, vol. 14, no. 4, Nov. 2022, https://doi.org/10.4081/dr.2022.9447.